El-Deyarbi Marwan, Ahmed Luai, King Jeffrey, Adi Zelal S, Al Juboori Ahmed, Mansour Nirmin A, Al Nuaimi Huda, Beiram Rami, Aburuz Salahdein
Department of Pharmacology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE.
Department of Pharmacy, Oud Al-Touba Diagnostic and Screening Clinic, Ambulatory Health Services, Abu Dhabi Health Services Co. (SEHA), Al Ain, UAE.
PLoS One. 2025 Jul 9;20(7):e0327211. doi: 10.1371/journal.pone.0327211. eCollection 2025.
Clinical evidence on the protective effects of a balanced diet, exercise, and medication adherence along with intensive glucose-lowering therapies on diabetes progression is lacking, and interventions that are most effective in slowing cardiorenal metabolic complications in patients with diabetes remain unelucidated.
To determine the effects of long-term multifactorial interventions on clinical outcomes in Emirati patients with diabetes attending ambulatory healthcare clinics.
We conducted a randomised controlled clinical trial at the Oud Al-Touba Clinic involving 192 participants with diabetes, who were blinded to the intervention and control groups, and followed up for 1 year. At the 3-, 6-, and 9-month visits, the intervention and control groups received multifactorial interventions and standard routine care, respectively. Glycated haemoglobin A1c (HbA1c) levels, estimated glomerular filtration rate (eGFR), blood pressure, electrolyte levels, and cardiovascular events were assessed at study completion.
During a mean follow-up of 11.9 months, 40.4% of the participants in the intervention group (31.6% in the control group) achieved diabetes control (HbA1c < 7%), with a significant mean difference of -0.36% in HbA1c levels between the groups (95% CI: -0.54 - -0.19, P < 0.01). Participants in the multifactorial group achieved a significant mean difference in low-density lipoprotein cholesterol levels (mean difference = -0.14, 95% CI: -0.27-0.001, P < 0.03), and significant adjusted mean difference of eGFR levels difference (3.93 mL/min/1.73 m2, 95% CI: 1.27-6.58, P < 0.01) at study completion compared to those in the control group. Moreover, the percentage of participants in the intervention group who met the blood pressure target increased from 38.3% to 51.1%, accompanied with a decrease in serum electrolyte levels, compared to 34.7% to 36.7% in the control group at the end of the follow-up.
Implementing multifactorial interventions by a multidisciplinary team improved several clinical manifestations, including HbA1c, SBP, and eGFR, and decreased cardiovascular risk factors despite the decreased diabetes medication use.
ClinicalTrials.gov NCT04942119.
缺乏关于均衡饮食、运动、药物依从性以及强化降糖治疗对糖尿病进展的保护作用的临床证据,且对于最有效地减缓糖尿病患者心脏肾脏代谢并发症的干预措施仍未明确。
确定长期多因素干预对阿联酋门诊糖尿病患者临床结局的影响。
我们在乌德图巴诊所进行了一项随机对照临床试验,纳入192例糖尿病参与者,他们对干预组和对照组不知情,并随访1年。在第3、6和9个月的访视中,干预组和对照组分别接受多因素干预和标准常规护理。在研究结束时评估糖化血红蛋白A1c(HbA1c)水平、估计肾小球滤过率(eGFR)、血压、电解质水平和心血管事件。
在平均11.9个月的随访期间,干预组40.4%的参与者(对照组为31.6%)实现了糖尿病控制(HbA1c<7%),两组间HbA1c水平的平均差异显著为-0.36%(95%CI:-0.54--0.19,P<0.01)。多因素干预组在低密度脂蛋白胆固醇水平上实现了显著的平均差异(平均差异=-0.14,95%CI:-0.27 - 0.001,P<0.03),并且在研究结束时,与对照组相比,eGFR水平的调整后平均差异显著(3.93 mL/min/1.73 m²,95%CI:1.27 - 6.58,P<0.01)。此外,干预组达到血压目标的参与者百分比从38.3%增加到51.1%,同时血清电解质水平降低,而对照组在随访结束时为34.7%至36.7%。
多学科团队实施多因素干预改善了包括HbA1c、收缩压和eGFR在内的多种临床表现,并降低了心血管危险因素,尽管糖尿病药物使用量减少。
ClinicalTrials.gov NCT04942119。